Advice
Following a full submission
peginterferon alfa-2a (Pegasys) is accepted for use within NHS Scotland in combination with ribavirin for the treatment of chronic hepatitis C in adult patients who have failed previous treatment with interferon alfa (pegylated or non-pegylated) alone or in combination with ribavirin.
Non-responders to previous hepatitis C treatment, predominantly with virus genotype 1, achieved sustained viral responses of 8% and 15% following 48 weeks and 72 weeks of combination treatment respectively.
The manufacturer did not provide comparative clinical or cost-effectiveness data versus peginterferon alfa-2b.
Download detailed advice95KB (PDF)
Medicine details
- Medicine name:
- peginterferon alfa-2a (Pegasys)
- SMC ID:
- 561/09
- Indication:
- Licence extension for re-treatment of hepatitis C
- Pharmaceutical company
- Roche
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Status
- Superseded
- Date advice published
- 10 August 2009